NCT07123727Phase 2Recruiting

A Study to Examine Anktiva for the Treatment of COVID-19.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-03Estimated

Enrollment · participants40Estimated

Source updated2026-09-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-09-24 · 1 field changed

Primary completion date

Recorded edit

− Previous value

2026-07

+ Updated value

2027-03

Check registry source

Study details

Conditions studied

Long COVID; Long COVID Syndrome; Long Covid 19

Treatments or interventions studied

AnktivaDrugAlso known as N-803, Nogapendekin Alfa Inbakicept, NAI

Primary outcomes · main study measures

Read the study measures

measure: Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.; timeFrame: Through 30 days post final study drug administration.; measure: Incidence of grade 3 or higher TEAEs through 30 days post final study drug administration.; timeFrame: Through 30 days post final study drug administration.; measure: Incidence of serious adverse events (SAEs) through 30 days post final study drug administration.; timeFrame: Through 30 days post final study drug administration.; measure: Incidence of abnormal changes in safety laboratory tests (CBC and CMP).; timeFrame: Through the end of the study treatment period (approximately 75 days).; measure: Clinically important changes in vital signs such as temperature in degrees Fahrenheit.; timeFrame: Through the end of the study treatment period (approximately 75 days).; measure: Clinically important changes in vital signs such as heart rate in beats per minute.; timeFrame: Through the end of the study treatment period (approximately 75 days).; measure: Clinically important changes in vital signs such as blood pressure in millimeters of mercury (mmHg).; timeFrame: Through the end of the study treatment period (approximately 75 days).; measure: Clinically important changes in vital signs such as respiratory rate in breaths per minute.; timeFrame: Through the end of the study treatment period (approximately 75 days).; measure: Clinically important changes in vital signs such as oxygen saturation in percentage.; timeFrame: Through the end of the study treatment period (approximately 75 days).

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history